{
    "clinical_study": {
        "@rank": "18497", 
        "arm_group": [
            {
                "arm_group_label": "CureXcell\u00ae", 
                "arm_group_type": "Experimental", 
                "description": "CureXcell\u00ae injection will be administered about every 4 weeks for up to 3 treatments, or until ulcer closure, whichever occurs first."
            }, 
            {
                "arm_group_label": "Placebo injection", 
                "arm_group_type": "Placebo Comparator", 
                "description": "The placebo will be administered by injecting normal saline at each centimeter of the ulcer bed."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective is to evaluate the clinical benefit of CureXcell\u00ae as adjunct to\n      Standard of Care in the treatment of Chronic Venous Leg Ulcers. CureXcell\u00ae is a cell based\n      therapy, containing activated homologous white blood cells prepared from donated healthy\n      whole blood. A total of 252 patients will be randomized to receive either CureXcell\u00ae or\n      Placebo."
        }, 
        "brief_title": "Evaluation of CureXcell\u00ae in Treating Chronic Venous Leg Ulcers", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Venous Leg Ulcers", 
        "condition_browse": {
            "mesh_term": [
                "Leg Ulcer", 
                "Ulcer", 
                "Varicose Ulcer"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ankle Brachial Pressure Index (ABI) \u2265 0.80\n\n          -  Venous insufficiency confirmed by duplex Doppler ultrasound\n\n          -  Presence of a venous leg ulcer, unresponsive to Standard of Care treatment for at\n             least 4 weeks and between \u2265 1 cm2 and \u2264 12cm2\n\n        Exclusion Criteria:\n\n          -  Target Ulcer has increased or decreased > 30% in size from Screening to Baseline\n\n          -  Documented history of osteomyelitis at the Target Ulcer location within 6 months\n             preceding the Baseline Visit.\n\n          -  Patients who are unable to tolerate multi-layer compression therapy.\n\n          -  Ulcer, which in the opinion of the Investigator is suspicious for cancer.\n\n          -  Any malignancy within the past 5 years, excluding successfully treated basal cell\n             carcinoma or squamous cell carcinoma without evidence of metastases.\n\n          -  History of radiation at the Target Ulcer site in previous 12 months prior to Baseline\n             Visit.\n\n          -  Patients with clinically significant claudication\n\n          -  Current sepsis\n\n          -  Patients with known history of significantly compromised immunity for any reason\n             including radiation therapy, chemotherapy or HIV"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "252", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02130310", 
            "org_study_id": "MC-105"
        }, 
        "intervention": [
            {
                "arm_group_label": "CureXcell\u00ae", 
                "description": "CureXcell\u00ae is a cell based therapy obtained from donated whole blood. The blood is collected from healthy young adults, the white blood cells are separated and then activated by hypo-osmotic shock.", 
                "intervention_name": "CureXcell\u00ae", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo injection", 
                "description": "Normal saline injected at each centimeter of ulcer bed", 
                "intervention_name": "Placebo injection", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Chronic ulcers", 
            "Venous ulcers"
        ], 
        "lastchanged_date": "May 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fresno", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hialeah", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "South Miami", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oak Park", 
                        "country": "United States", 
                        "state": "Illinois"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Las Vegas", 
                        "country": "United States", 
                        "state": "Nevada"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wyomissing", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "McAllen", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell\u00ae as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers", 
        "other_outcome": {
            "description": "Incidence of adverse events, including overall AEs, AEs related to the CureXcell\u00ae and study-ulcer-associated AEs.", 
            "measure": "Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "up to 24 weeks"
        }, 
        "overall_contact": {
            "email": "kushd@amarexcro.com", 
            "last_name": "Kush Dhody", 
            "phone": "301-956-2536"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Miami", 
                "last_name": "Robert Kirsner, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "St. Luke's-Roosevelt Hospital Center", 
                "last_name": "John Lantis, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Barry University Clinical Research", 
                "last_name": "Robert Snyder, DPM", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Time to complete closure of Target Ulcer at any time during the 12-week Treatment Phase. Complete closure is confirmed at two consecutive study visits two weeks apart.", 
            "measure": "Time to complete closure of Target Ulcer", 
            "safety_issue": "No", 
            "time_frame": "up to 16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02130310"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Proportion of complete closure of Target Ulcer within the Treatment Phase. Complete closure is confirmed at two consecutive study visits two weeks apart.", 
                "measure": "Proportion of complete closure of Target Ulcer", 
                "safety_issue": "No", 
                "time_frame": "up to 16 weeks"
            }, 
            {
                "description": "Percentage change from baseline in Target Ulcer surface area at the end of the Treatment Phase.", 
                "measure": "Percentage change from baseline in Target Ulcer surface area", 
                "safety_issue": "No", 
                "time_frame": "up to 12 weeks"
            }, 
            {
                "description": "Proportion of Target Ulcer recurrence during the 12-week Follow-Up Phase.", 
                "measure": "Proportion of Target Ulcer recurrence", 
                "safety_issue": "No", 
                "time_frame": "up to 24 weeks"
            }
        ], 
        "source": "Macrocure Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Macrocure Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}